NovAccess Global Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XSNX research report →
Price Chart
About the company
Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States. Their primary expertise is in pioneering research that leverages a patient's own immune system to target and eliminate cancerous cells.
- CEO
- Dwain K. Morris-Irvin
- IPO
- 1998
- Employees
- 2
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on XSNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.33K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -2.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 76.60%
- ROIC
- -0.01%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-2,466,760
- Net Income
- $-4,769,187-177.9%
- EPS
- $-0.23-130.0%
- OCF Growth
- +30.9%
- FCF Growth
- +30.9%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.80
- RSI (14)
- 100
- Avg Volume
- 1.33K
No earnings-call transcripts are available for XSNX yet.
- Free Float
- 42.7%
- Shares Outstanding
- 61.65M
- Float Shares
- 26.32M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 17, 24 | Sumner David | other | 0 |
| May 31, 24 | CASSARINI JOHN | other | 0 |
| Mar 13, 23 | LAIRD NEIL J | other | 428,571 |
| Mar 13, 23 | CASSARINI JOHN | other | 857,143 |
| Mar 13, 23 | Anderson Jason Michael | other | 857,143 |
| Mar 18, 22 | Anderson Jason Michael | other | 0 |
| Mar 14, 22 | CASSARINI JOHN | other | 0 |
| Mar 14, 22 | Martin Daniel G. | other | 1,502,670 |
| Mar 14, 22 | Martin Daniel G. | other | 25,000 |
| Mar 14, 22 | Martin Daniel G. | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XSNX coverage
Recent articles, reports, and earnings notes.
No research on XSNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XSNX report →Financial Contrast: NovAccess Global (OTCMKTS:XSNX) vs. Lexicon Pharmaceuticals (NASDAQ:LXRX)
defenseworld.net · Jan 26
NovAccess Global (OTCMKTS:XSNX) versus Roivant Sciences (NASDAQ:ROIV) Financial Review
defenseworld.net · Jan 18
NovAccess Global Advisory on Annual Meeting of Shareholders
accesswire.com · May 7
NovAccess Global Announces New License to Advance its Immunotherapy Platform
accesswire.com · Apr 30
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
accesswire.com · Mar 1
NovAccess Global Announces $10.7 Million Financing
accesswire.com · Jan 2
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
newsfilecorp.com · Dec 1
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
accesswire.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.